David Fredrickson, AstraZeneca

WCLC: As­traZeneca builds case for grow­ing ADC pipeline with dou­ble wins in ad­vanced lung can­cer

As part of its hard piv­ot to on­col­o­gy in re­cent years, As­traZeneca made a big bet on next-gen can­cer fight­ers with a multi­bil­lion-dol­lar deal in ear­ly 2019 with Dai­ichi Sankyo for its an­ti­body-drug con­ju­gates. The orig­i­nal­ly tar­get­ed ther­a­py has al­ready made good on its mar­ket promise, and now As­traZeneca has high hopes for an­oth­er.

As­traZeneca’s TROP2 tar­get­ing datopotam­ab derux­te­can post­ed 32 com­plete or par­tial re­spons­es in metasta­t­ic non-small cell lung can­cer and an ad­di­tion­al five that were still too ear­ly to con­firm, ac­cord­ing to da­ta from the Phase I TRO­PI­ON-Pan­Tu­mor01 tri­al pre­sent­ed Fri­day at the vir­tu­al World Con­gress on Lung Can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.